Devita, Hellman, and Rosenberg's Cancer

LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21

124 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 11.4. Which of the following is an appropriate strategy for optimizing high-dose

methotrexate elimination?

A. Initiate leucovorin rescue immediately after completion of infusion

of methotrexate

B. Administer intravenous fluids prior to methotrexate infusion

C. Ensure the patient is taking folic acid 1 mg by mouth daily

D. Administer intravenous fluids with sodium bicarbonate for urine

alkalinization

Question 11.5. Which of the following medications are necessary to help minimize hema-

tologic toxicities with pemetrexed and pralatrexate?

A. Vitamin B 6 and Vitamin B 12

B. Folic acid and dexamethasone

C. Vitamin B 12 and folic acid

D. Folinic acid and Vitamin B 6

Question 11.6. A patient with stage III colon cancer is day 10 after receiving FOLFIRI

chemotherapy and presents to the hospital with a 3-day history of profuse

diarrhea, severe mucositis, and an ANC of zero. Which of the following

is the most likely cause of his symptoms?

A. The patient is likely homozygous for UGT1A1*28

B. Irinotecan-induced delayed diarrhea

C. DPD deficiency

D. FOLFIRI-induced myelosuppression and GI toxicity

Question 11.7. Which one of the following chemotherapy agents requires prophylaxis

againstPneumocystis carinii?

A. Gemcitabine

B. Fludarabine

C. Cytarabine

D. Clofarabine

Question 11.8. Which of the following is NOT a proposed mechanism for cardiotoxicity

from anthracyclines?

A. Enhanced catalysis of oxidation-reduction reactions

B. Increased susceptibility to p-glycoprotein

C. Generation of reactive oxygen species

D. Peroxidation of myocardial lipids

Question 11.9. Which of the following is most consistent with a proposed advantage of

cabazitaxel over other approved taxane chemotherapy agents?

A. It is a poor substrate for multidrug-resistant p-glycoprotein

B. There is a smaller incidence of peripheral neuropathy

C. Increased response rate with cabazitaxel over docetaxel

D. Lower incidence of febrile neutropenia